High Court ‘Skinny Label’ Ruling Is No Generic Drug Free-for-All

The US Supreme Court’s June 4 ruling in Hikma v. Amarin is a consequential decision for the pharmaceutical industry. It carries implications for branded and generic manufacturers and cautions courts against penalizing ordinary commercial activity for being an active inducement of patent infringement.

The case sits at the intersection of patent law, Food and Drug Administration labeling rules, state substitution laws, and the commercial realities of launching a generic that cuts into the sales of the branded drug.

Hikma Pharmaceuticals USA Inc. had launched a generic version of the branded drug Vascepa with a so-called skinny label, seeking approval for only one FDA-approved indication while “carving out” other indications that are protected by method-of-use patents. These carve-outs limit a branded manufacturer’s ability to sue for infringement of method-of-use patents that cover the excluded indications.

However, under state substitution laws, the generic product can still be prescribed for the patented indications that were carved out of the generic version. This cuts into the branded manufacturers’ market share.

Amarin Pharma Inc. sued Hikma, claiming that even with a skinny label, Hikma could induce physicians to infringe the method-of-use patents covering the carved-out indications. Had Amarin succeeded, the generic industry would have faced higher costs and delays in launching lower-cost equivalents to branded products.

Despite Hikma’s victory, generic manufacturers shouldn’t see the decision as an open invitation to encourage marketing for off-label uses. Rather, the ruling should be viewed as a limited safe harbor against liability when generic manufacturers comply with routine regulatory obligations and commercial realities of the marketplace.

There are important takeaways for the pharmaceutical industry, both on the brand and generic side.

Marketing strategy: While Hikma mitigated the risk from skinny labels, it doesn’t open the door for off-label promotion of carved-out indications. Even before launching the product, generic manufacturers should start maintaining a clean record of communications with the FDA as to the label carve-outs, regulating internal discussion on off-label use, and ensuring that the language in marketing and sales statements is limited to conventional commercial practices and closely tied to the approved labeling.

The justices rejected Hikma’s argument that active inducement had to be “express.” Therefore, promoting off-label uses, such as through marketing materials targeted toward healthcare providers, could still impose liability on the generic company under Hikma.

Litigation strategy: Patentees should critically evaluate evidence needed to plead affirmative steps taken by the accused infringer. Amarin had relied on Metro-Goldwyn-Mayer Studios Inc. v. Grokster as an example of affirmative conduct. But the justices rejected this comparison and instead highlighted the differences in the conduct alleged in Grokster versus in Hikma.

In Grokster, the distributor of free file-sharing software “sent users a newsletter promoting its ability to provide particular, popular copyrighted materials.” Another infringing file-sharing service had advertisements “beamed onto the computer screens of users.”

By contrast, Amarin could point only to Hikma’s inclusion of a clinical study and safety warnings involving the carved-out use and press releases about its product without referencing the carved-out indications.

The Supreme Court found Amarin’s factual allegations insufficient. It emphasized that the contents of the label were FDA-mandated and noted the press release was consistent with routine commercial practice. Its analysis highlights the importance of looking beyond sufficiency of the facts and into the regulatory and commercial realities of the marketplace.

If the conduct is consistent with the needs of “regular commerce,” then Hikma may offer a shield against allegations of sellers actively inducing infringement.

Patent prosecution strategy: While method-of-use patents are valuable, they may be difficult to enforce against skinny labels absent evidence of active promotion by the generic manufacturer of the carved-out indications. Brand companies may be able to maximize method-of-use patents’ value by adopting strategic claim drafting and continuation applications that map onto substantial portions of the generic label.

However, mapping claims onto portions of the generic label may be insufficient where the FDA mandates inclusion of such portions, and the Supreme Court may view the label as passive compliance with regulatory practice, rather than active inducement to infringe.

Hikma has drawn strong reactions within the pharmaceutical industry, but its implications extend beyond generic drug labeling. At its heart, the ruling reflected the Supreme Court’s reluctance to “trench[] on regular commerce” and create a risk where even routine commercial activities or compliance with legal obligations could support a finding of induced infringement.

While courts will have to dissect what constitutes routine activities versus affirmative encouragement on a case-by-case basis, Hikma raises the bar for patentees to plead induced infringement.

The case is Hikma Pharms. USA Inc. v. Amarin Pharma, Inc., U.S., No. 24-889, decided 6/4/26.

Reproduced with permission. Published June 18, 2026. Copyright 2026 Bloomberg Industry Group, Inc. 800-372-1033. For further use please visit https://www.bloombergindustry.com/copyright-and-usage-guidelines-copyright/